Finance

Beta
Lists
PX91:FRA
Filana Therapeutics Inc
€0.94
-5.07%
(-0.050) 1D
Jul 15, 8:02:45 AM GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for PX91...
Open
€0.94
High
€0.94
Low
€0.94
Mkt. cap
52.66M
Avg. vol.
338.00
Volume
0.00
52-wk high
€3.90
52-wk low
€0.94
No. of employees
19
Open
€0.94
High
€0.94
Low
€0.94
Mkt. cap
52.66M
Avg. vol.
338.00
Volume
0.00
52-wk high
€3.90
52-wk low
€0.94
No. of employees
19
News stories
From sources across the web
Profile
Filana Therapeutics, Inc. is an American pharmaceutical company based in Austin, Texas. The company's stated mission is "developing transformative medicines to improve the lives of patients with central nervous system disorders." Currently led by President & CEO Richard Barry, Filana is working on developing simufilam to treat tuberous sclerosis complex-related epilepsy. Filana Therapeutics was founded in 1998 by Remi Barbier as Pain Therapeutics, Inc., changing its name in 2019 to Cassava Sciences. The company initially worked on three drugs: the pain drugs Oxytrex and Remoxy, and PTI-901, which aimed to treat irritable bowel syndrome. It began developing simufilam, as an oral-tablet drug candidate for the treatment of Alzheimer's disease. The company has had no drug approved. In 2021, with 25 employees, the company's stock was the sixth-best performing in the U.S. before falling after concerns surfaced over simufilam research. Development of simufilam was discontinued in November 2024 after the first phase III clinical trial failed; it was the company's only drug undergoing clinical trials. Wikipedia
About Filana Therapeutics Inc
CEO-
Employees19
Founded1998
HeadquartersAustin, Texas, United States
SectorPharmaceutical industry
Websitepaintrials.com
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
-
-
-
-
Cost of goods sold
5.12M
3.96M
3.85M
4.54M
Cost of revenue
5.12M
3.96M
3.85M
4.54M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
8.98M
7.90M
5.70M
6.62M
Operating expense
8.98M
7.90M
5.70M
6.62M
Total operating expenses
14.09M
11.86M
9.55M
11.17M
Operating income
-14.09M
-11.86M
-9.55M
-11.17M
Other non operating income
-46.00K
-114.00K
39.00K
48.00K
EBT including unusual items
-44.22M
-10.81M
-12.54M
-10.33M
EBT excluding unusual items
-12.92M
-10.81M
-8.54M
-10.33M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-44.22M
-10.81M
-12.54M
-10.33M
Net profit margin
-
-
-
-
Earnings per share
-
-
-
-
Interest and investment income
1.21M
1.17M
974.00K
789.00K
Interest expense
-
-
-
-
Net interest expenses
1.21M
1.17M
974.00K
789.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-13.87M
-11.73M
-9.18M
-10.92M
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer